Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.

Algarín EM, Díaz-Tejedor A, Mogollón P, Hernández-García S, Corchete LA, San-Segundo L, Martín-Sánchez M, González-Méndez L, Schoumacher M, Banquet S, Kraus-Berthier L, Kloos I, Derreal A, Halilovic E, Maacke H, Gutiérrez NC, Mateos MV, Paíno T, Garayoa M, Ocio EM.

Haematologica. 2019 Jul 18. pii: haematol.2018.212308. doi: 10.3324/haematol.2018.212308. [Epub ahead of print]

2.

Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.

Pierrillas PB, Henin E, Ball K, Ogier J, Amiel M, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

Drug Metab Dispos. 2019 Jun;47(6):648-656. doi: 10.1124/dmd.118.085605. Epub 2019 Apr 2.

PMID:
30940629
3.

Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in Mice.

Pierrillas PB, Henin E, Ogier J, Kraus-Berthier L, Chenel M, Bouzom F, Tod M.

J Pharmacol Exp Ther. 2018 Dec;367(3):414-424. doi: 10.1124/jpet.118.251694. Epub 2018 Sep 18.

PMID:
30228112
4.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.

Leukemia. 2019 Apr;33(4):905-917. doi: 10.1038/s41375-018-0261-3. Epub 2018 Sep 10.

5.

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJS, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O.

Oncotarget. 2018 Apr 13;9(28):20075-20088. doi: 10.18632/oncotarget.24744. eCollection 2018 Apr 13.

6.

Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.

Markozashvili D, Pichugin A, Barat A, Camara-Clayette V, Vasilyeva NV, Lelièvre H, Kraus-Berthier L, Depil S, Ribrag V, Vassetzky Y.

Gene. 2016 Apr 15;580(2):134-143. doi: 10.1016/j.gene.2016.01.017. Epub 2016 Jan 13.

PMID:
26774800
7.

Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine.

Tian W, Yougnia R, Depauw S, Lansiaux A, David-Cordonnier MH, Pfeiffer B, Kraus-Berthier L, Léonce S, Pierré A, Dufat H, Michel S.

J Med Chem. 2014 Dec 26;57(24):10329-42. doi: 10.1021/jm500927d. Epub 2014 Dec 9.

PMID:
25360689
8.

Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.

Gressette M, Vérillaud B, Jimenez-Pailhès AS, Lelièvre H, Lo KW, Ferrand FR, Gattolliat CH, Jacquet-Bescond A, Kraus-Berthier L, Depil S, Busson P.

PLoS One. 2014 Mar 11;9(3):e91325. doi: 10.1371/journal.pone.0091325. eCollection 2014.

9.

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Némati F, de Montrion C, Lang G, Kraus-Berthier L, Carita G, Sastre-Garau X, Berniard A, Vallerand D, Geneste O, de Plater L, Pierré A, Lockhart B, Desjardins L, Piperno-Neumann S, Depil S, Decaudin D.

PLoS One. 2014 Jan 13;9(1):e80836. doi: 10.1371/journal.pone.0080836. eCollection 2014.

10.

The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.

Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C.

Clin Cancer Res. 2013 Dec 1;19(23):6520-31. doi: 10.1158/1078-0432.CCR-13-0877. Epub 2013 Oct 18.

11.

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.

Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, Lelièvre H, Depil S, Dessen P, Solary E, Raslova H, Vainchenker W, Plo I, Debili N.

Cell Death Dis. 2013 Jul 25;4:e738. doi: 10.1038/cddis.2013.260.

12.

Influence of the stereoisomeric position of the reactive acetate groups of the benzo[b]acronycine derivative S23906-1 on its DNA alkylation, helix-opening, cytotoxic, and antitumor activities.

Depauw S, Gaslonde T, Léonce S, Kraus-Berthier L, Laine W, Lenglet G, Chiaroni A, Pfeiffer B, Bailly C, Michel S, Tillequin F, Pierré A, David-Cordonnier MH.

Mol Pharmacol. 2009 Dec;76(6):1172-85. doi: 10.1124/mol.109.057554. Epub 2009 Sep 14.

PMID:
19752199
13.

Synthesis, cytotoxic activity, and DNA binding properties of antitumor cis-1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine cinnamoyl esters.

Do Q, Tian W, Yougnia R, Gaslonde T, Pfeiffer B, Pierré A, Léonce S, Kraus-Berthier L, David-Cordonnier MH, Depauw S, Lansiaux A, Mazinghien R, Koch M, Tillequin F, Michel S, Dufat H.

Bioorg Med Chem. 2009 Mar 1;17(5):1918-27. doi: 10.1016/j.bmc.2009.01.062. Epub 2009 Jan 31.

PMID:
19217791
14.

Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.

Lansiaux A, Léonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, David-Cordonnier MH, Hautefaye P, Lavielle G, Bailly C, Hickman JA, Pierré A.

Mol Pharmacol. 2007 Aug;72(2):311-9. Epub 2007 May 9.

PMID:
17494837
15.

Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1.

Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier MH, Tardy C, Lansiaux A, Poindessous V, Larsen AK, Pierré A.

Cancer Res. 2006 Jul 15;66(14):7203-10.

16.

Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine.

Nguyen TM, Sittisombut C, Boutefnouchet S, Lallemand MC, Michel S, Koch M, Tillequin F, Mazinghien R, Lansiaux A, David-Cordonnier MH, Pfeiffer B, Kraus-Berthier L, Léonce S, Pierré A.

J Med Chem. 2006 Jun 1;49(11):3383-94.

PMID:
16722658
17.

Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.

Duca M, Guianvarc'h D, Meresse P, Bertounesque E, Dauzonne D, Kraus-Berthier L, Thirot S, Léonce S, Pierré A, Pfeiffer B, Renard P, Arimondo PB, Monneret C.

J Med Chem. 2005 Jan 27;48(2):593-603.

PMID:
15658872
18.

Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues.

Guillonneau C, Nault A, Raimbaud E, Léonce S, Kraus-Berthier L, Pierré A, Goldstein S.

Bioorg Med Chem. 2005 Jan 3;13(1):175-84.

PMID:
15582462
19.

Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.

Bal C, Baldeyrou B, Moz F, Lansiaux A, Colson P, Kraus-Berthier L, Léonce S, Pierré A, Boussard MF, Rousseau A, Wierzbicki M, Bailly C.

Biochem Pharmacol. 2004 Nov 15;68(10):1911-22.

PMID:
15476662
20.

Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin.

Guianvarc'h D, Duca M, Boukarim C, Kraus-Berthier L, Léonce S, Pierré A, Pfeiffer B, Renard P, Arimondo PB, Monneret C, Dauzonne D.

J Med Chem. 2004 Apr 22;47(9):2365-74.

PMID:
15084135
21.

Ex vivo differentiated endothelial and smooth muscle cells from human cord blood progenitors home to the angiogenic tumor vasculature.

Le Ricousse-Roussanne S, Barateau V, Contreres JO, Boval B, Kraus-Berthier L, Tobelem G.

Cardiovasc Res. 2004 Apr 1;62(1):176-84.

PMID:
15023564
22.

Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents.

Lisowski V, Léonce S, Kraus-Berthier L, Sopková-de Oliveira Santos J, Pierré A, Atassi G, Caignard DH, Renard P, Rault S.

J Med Chem. 2004 Mar 11;47(6):1448-64.

PMID:
14998333
23.

Synthesis and cytotoxic and antitumor activity of 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine diacid hemiesters and carbamates.

Doan Thi Mai H, Gaslonde T, Michel S, Koch M, Tillequin F, Pfeiffer B, Renard P, Kraus-Berthier L, Léonce S, Pierré A.

Chem Pharm Bull (Tokyo). 2004 Mar;52(3):293-7.

24.

Synthesis of mono- and bisdihydrodipyridopyrazines and assessment of their DNA binding and cytotoxic properties.

Blanchard S, Rodriguez I, Tardy C, Baldeyrou B, Bailly C, Colson P, Houssier C, Léonce S, Kraus-Berthier L, Pfeiffer B, Renard P, Pierré A, Caubère P, Guillaumet G.

J Med Chem. 2004 Feb 12;47(4):978-87.

PMID:
14761199
25.

Structure-activity relationships and mechanism of action of antitumor benzo[b]pyrano[3,2-h]acridin-7-one acronycine analogues.

Thi Mai HD, Gaslonde T, Michel S, Tillequin F, Koch M, Bongui JB, Elomri A, Seguin E, Pfeiffer B, Renard P, David-Cordonnier MH, Laine W, Bailly C, Kraus-Berthier L, Léonce S, Hickman JA, Pierré A.

J Med Chem. 2003 Jul 3;46(14):3072-82.

PMID:
12825945
26.

Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.

Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.

Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. Epub 2002 Jun 25.

PMID:
12172972
27.

Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A.

Clin Cancer Res. 2001 Aug;7(8):2573-80.

28.

[New approaches in experimental cancerology: in search of therapeutic models].

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Pierré A, Hickman J.

Bull Cancer. 2001 Jan;88(1):75-84. French. No abstract available.

29.

Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine.

Costes N, Le Deit H, Michel S, Tillequin F, Koch M, Pfeiffer B, Renard P, Léonce S, Guilbaud N, Kraus-Berthier L, Pierré A, Atassi G.

J Med Chem. 2000 Jun 15;43(12):2395-402.

PMID:
10882366
30.

Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.

Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G.

Clin Cancer Res. 2000 Jan;6(1):297-304.

31.
32.

Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity.

Guillonneau C, PierréA, Charton Y, Guilbaud N, Kraus-Berthier L, Léonce S, Michel A, Bisagni E, Atassi G.

J Med Chem. 1999 Jun 17;42(12):2191-203.

PMID:
10377224
33.

Experimental antitumour activity of S 16020-2 in a panel of human tumours.

Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G.

Eur J Cancer. 1997 Oct;33(11):1881-7.

PMID:
9470851
34.

Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.

Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierré A, Atassi G.

Anticancer Drugs. 1997 Mar;8(3):276-82.

PMID:
9095333
35.

Up-regulated expression of the beta3 integrin and the 92-kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice.

Gouon V, Tucker GC, Kraus-Berthier L, Atassi G, Kieffer N.

Int J Cancer. 1996 Nov 27;68(5):650-62.

36.

Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.

Elomri A, Mitaku S, Michel S, Skaltsounis AL, Tillequin F, Koch M, Pierré A, Guilbaud N, Léonce S, Kraus-Berthier L, Rolland Y, Atassi G.

J Med Chem. 1996 Nov 22;39(24):4762-6.

PMID:
8941390
37.

Synthesis and biological evaluation of 6-(9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazol-1-yl)picolinic amides as new olivacine derivatives.

Landras C, Jasztold-Howorko R, Pierré A, Léonce S, Guilbaud N, Kraus-Berthier L, Guillonneau C, Rolland Y, Atassi G, Bisagni E.

Chem Pharm Bull (Tokyo). 1996 Nov;44(11):2169-72.

PMID:
8945783
38.

New purines and purine analogs as modulators of multidrug resistance.

Dhainaut A, Regnier G, Tizot A, Pierre A, Leonce S, Guilbaud N, Kraus-Berthier L, Atassi G.

J Med Chem. 1996 Sep 27;39(20):4099-108.

PMID:
8831775
39.

In vivo antitumor activity of S 16020-2, a new olivacine derivative.

Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G.

Cancer Chemother Pharmacol. 1996;38(6):513-21.

PMID:
8823492
40.

Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N- [(dialkylamino)alkyl]carboxamides, a new promising series of antitumor olivacine derivatives.

Jasztold-Howorko R, Landras C, Pierré A, Atassi G, Guilbaud N, Kraus-Berthier L, Léonce S, Rolland Y, Prost JF, Bisagni E.

J Med Chem. 1994 Jul 22;37(15):2445-52.

PMID:
8057291
41.

In vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324.

Kraus-Berthier L, Guilbaud N, Peglion JL, Leonce S, Lombet A, Pierre A, Atassi G.

Acta Oncol. 1994;33(6):631-7.

PMID:
7946440
42.

In vivo immunopharmacological properties of tuftsin and four analogs.

Kraus-Berthier L, Rémond G, Visalli M, Héno D, Portevin B, Vincent M.

Immunopharmacology. 1993 May-Jun;25(3):261-7.

PMID:
8354642
43.

In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative.

Pierré A, Dunn TA, Kraus-Berthier L, Léonce S, Saint-Dizier D, Régnier G, Dhainaut A, Berlion M, Bizzari JP, Atassi G.

Invest New Drugs. 1992 Aug;10(3):137-48.

PMID:
1428723
44.

New triazine derivatives as potent modulators of multidrug resistance.

Dhainaut A, Régnier G, Atassi G, Pierré A, Léonce S, Kraus-Berthier L, Prost JF.

J Med Chem. 1992 Jun 26;35(13):2481-96.

PMID:
1352353
45.

Approaches to some biochemical mechanisms of action of tuftsin and analogues.

Kraus-Berthier L, Ferry G, Combe-Perez V, Visalli M, Remond G, Vincent M, Boutin JA.

Biochem Pharmacol. 1991 May 15;41(10):1411-8.

PMID:
1850275
46.

Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Pierré A, Kraus-Berthier L, Atassi G, Cros S, Poupon MF, Lavielle G, Berlion M, Bizzari JP.

Cancer Res. 1991 May 1;51(9):2312-8.

Supplemental Content

Loading ...
Support Center